Kiniksa Pharmaceuticals, Ltd. KNSA 深 沪
等待开盘 10-10 09:30:00 美东时间
80.02
+1.270
+1.61%
华盛通- 最 高80.50
- 今 开78.24
- 成交量 20.35万股
- 最 低 78.23
- 昨 收 78.75
- 总市值 62.43亿
- 52周最高 82.94
- 市盈率 静 107.11
- 换手率 0.26%
- 52周最低 35.20
- 委 比 -42.14%
- 总股本 7802.40万
- 历史最高 82.94
- 量 比 0.75
- 振 幅 2.88%
- 历史最低 5.01
- 每 手 1
- 风险率 14.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will be webcast live on the company's website, with a replay available within 48 hours. Kiniksa focuses on developing novel therapies for unmet medical needs, particularly in cardiovascular diseases.
09-04 20:01
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 9:00 a.m. ET. A live webcast and replay of the presentation will be available on the company’s website. Kiniksa is a biopharmaceutical company focused on developing novel therapies for diseases with unmet needs, particularly in cardiovascular indications.
08-07 20:01
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.
07-31 02:42
美股牛股 | AI基建股IOND首日升近26%，为21年来最大直接上市项目；Lucid劲升21%
AI基建股IOND首日升近26%，为21年来最大直接上市项目；医药股PMN飙升23%，阿尔茨海默病药物试验结果积极；Lucid劲升21%，获沙特首富1.3亿美元投资>>
07-29 19:00
Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst
Kiniksa Pharmaceuticals (KNSA) added nearly 50% on Tuesday after posting another quarterly beat and guidance boost with its financials, thanks mainly to Arcalyst, a heart disease therapy it markets wi...
07-29 02:29
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. This is a 30.43 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $243.600...
07-28 19:31
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.
07-28 19:30
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.
07-24 00:12
